Document:

EX-10.2

 Exhibit 10.2 

SEPARATION AGREEMENT 
 AND GENERAL
RELEASE 
 THIS SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is between Veru Inc. (“Company”) and Daniel T.
Haines (“Employee”). The effective date of this Agreement shall be the latter of the two signature dates evidenced on page eight hereof (“Effective Date”). 

RECITALS 

A.    Employee has submitted his resignation from the position of Chief Financial Officer of the Company effective as of
January 4, 2018. As a result, Employee’s employment with the Company ended effective as of January 4, 2018 (the “Separation Date”). 

B.    The Company and Employee desire to effect a final resolution and settlement of all matters and issues relating
directly or indirectly to Employee’s employment with the Company and Employee’s separation from that employment as of the Separation Date and have arrived at a compromise of all such matters in this Agreement. 

AGREEMENTS 

1.    Acknowledgment of Compensation through Date of Agreement. Employee acknowledges and agrees that with payment
by the Company to Employee of $26,565.24 gross, less tax withholding and all required deductions, on the next regularly scheduled payroll date after the Separation Date, an amount representing Employee’s outstanding earned wages to the
Separation Date of $3,846.15, an amount representing unused vacation to the Separation Date of $18,565.09, and expense reimbursement of $4,154.00, Employee will have received from the Company and its related entities all salary, fringe benefits
(including without limitation by enumeration vacation pay, expense reimbursement, and retirement plan contributions except as enumerated herein) and all other compensation and benefits owed by the Company to Employee to the Separation Date, other
than the bonus described in paragraph 2 hereof. Notwithstanding the foregoing, the Company expressly acknowledges and agrees that it will continue to honor any indemnification, advancement and similar obligations it may have to Employee under
law or under the Company’s Amended and Restated Articles of Incorporation, as amended, or the Company’s Amended and Restated By-Laws, as amended, or any directors’ and officers’ insurance
coverage (collectively, the “Unreleased Rights”). 
 2.    Bonus. In lieu of an equity award
representing Employee’s 2017 fiscal year bonus that would not vest until December 14, 2018 as approved by the Compensation Committee of the Company’s Board of Directors (“Compensation Committee”), the Company will pay
Employee the cash amount representing Employee’s outstanding fiscal year 2017 bonus of $80,888.00 gross less tax withholding and all required deductions within fifteen (15) days of closing on a future financing that nets the Company at
least $8 million in gross cash proceeds. “Financing” referred to herein represents external capital funded after the Separation date, whether in debt, equity, or otherwise and whether in one or a series of transactions that aggregate
at least $8 million in gross cash proceeds to the Company. Financing shall exclude any funding derived from customary operating activities, including any sale or settlement of trade receivables. 

 3.    Consideration. Conditioned upon (1) Employee’s signing
of this Agreement and Employee’s return of the Agreement to the Company, (2) providing reasonable and limited transition assistance services (including answering phone inquiries) as needed until March 31, 2018 and (3) Employee
returning his Company computer to Dawn Fitzpatrick in the Miami office, the Company shall: 
 (a)    pay Employee a
separation payment in an amount equal to his base salary for a period of six (6) months, which is equal to $125,000.00 (gross) in total, less tax withholding and all required deductions, which amount shall be paid in twelve (12) equal bi-monthly installments on each of the twelve (12) next regularly scheduled payroll dates commencing on the next regularly scheduled payroll date following Employee’s proper execution and return of this
agreement to the Company; and 
 (b)    accelerate the vesting of part of the
non-qualified stock option granted to Employee under the Company’s 2017 Equity Incentive Plan on August 2, 2017 with an exercise price of $1.20 per share (the “August 2017 Stock
Option”) that is scheduled to vest on August 2, 2018 (116,667 shares) so that such part of the August 2017 Stock Option is exercisable as of the Effective Date and permit such part of the August 2017 Stock Option to be exercised
for a period of one year from the Effective Date in accordance with the terms of the 2017 Equity Incentive Plan and the stock option grant agreement. 

Employee acknowledges that the remainder of the August 2017 Stock Option that is scheduled to vest on August 2, 2019 and August 2, 2020
(233,333 shares) shall terminate as of the Effective Date and may not be exercised. 
 The consideration specified in this paragraph 3 shall not be
deemed “compensation” for purposes of any of the Company’s qualified retirement plans or other benefit programs, and payment of this consideration does not entitle Employee to any retirement plan contributions by the Company for
Employee’s benefit or account. The consideration specified in this paragraph 3 is not an amount to which Employee is otherwise entitled, and constitutes additional consideration for Employee’s release and waiver of potential claims
identified in paragraph 6 below. 
 4.    Confidentiality and
Non-Disclosure 
 (a)    Employee agrees that this Agreement, and its terms
and provisions, are strictly confidential and shall not be divulged or disclosed in any way to any person other than Employee’s spouse, legal counsel, or tax advisor. Should Employee choose to divulge the terms and conditions of this Agreement
to Employee’s spouse, legal counsel, or tax advisor, Employee shall ensure that they will be similarly bound to keep the same confidential. A breach of this paragraph by Employee’s spouse, legal counsel, or tax advisor shall be considered
a breach of this paragraph by Employee. 
 5.    Non-Admission of
Liability. Neither this Agreement nor any action taken by the Company pursuant to it shall in any way be construed as an admission by the Company of any liability, wrongdoing, or violation of law, regulation, contract or policy regarding any of
the Company’s decisions and actions regarding the employment or separation from employment of Employee. 

  
 2 

 6.    Release and Waiver of Claims. For valuable consideration from
the Company as stated above, Employee, for Employee and Employee’s heirs, personal representatives, successors and assigns, hereby releases all claims of whatever nature that Employee may have against the Company, its parent company,
affiliates, subsidiaries, predecessors, successors and assigns and its and their present, former or later insurers, agents, representatives, officers, administrators, directors, shareholders and employees (collectively “Releases”), which
arise out of or are in any manner based upon or related to the employment relationship between Employee and the Company, and the end of that relationship, and from all other claims or liabilities of any nature whatsoever which have arisen from any
occurrence, transaction, omission or communication which transpired or occurred at any time before or on the date of this Agreement; provided, however, that (a) this Agreement will not prevent any party from asserting a claim against the other
party for breach of this Agreement and (b) the release and waiver of claims in this paragraph excludes, and the Employee does not release or waive: (i) any claims that cannot be released or waived by law; and (ii) any Unreleased
Rights. 
 7.    No Limitation of Rights. The waiver and release in paragraph 6 does not
affect those rights or claims that arise after the execution of this Agreement. Nor does the waiver and release affect those rights or claims that cannot be waived by law. While nothing contained in this Agreement shall be interpreted to prevent the
United States Equal Employment Opportunity Commission (“EEOC”) from investigating and pursuing any matter which it deems appropriate, Employee understands and agrees that, by signing this Agreement, Employee is waiving any and all rights
Employee may have to reinstatement, damages, remedies, costs, attorney’s fees or other relief as to any claims Employee has released and any rights Employee has waived as a result of Employee’s execution of this Agreement. Nothing
contained in this Agreement is intended to limit Employee’s right or ability to file a charge of discrimination with the EEOC. The EEOC has the authority to carry out its statutory duties by investigating the charge, issuing a determination,
filing a lawsuit in court in its own name, or taking any other action authorized under law. Employee retains the right to testify, assist or participate in any such action. Employee retains the right to communicate with the EEOC and such
communication can be initiated by Employee or in response to the government and is not limited by the non-disparagement obligations contained in paragraph 13 of this Agreement. 

8.    Unemployment Compensation and No Reinstatement, Reemployment or Rehire. Employer will not contest
Employee’s entitlement to receive unemployment compensation benefits based on the termination of employment. Employee expressly declines reinstatement, reemployment or rehire by the Company and waives all rights to claim such relief. If
Employee should apply for employment with the Company or with any of its related entities in the future, Employee agrees that Employee has no entitlement to such employment and may be denied employment based on this Agreement. 

9.    No Pending Matters. Employee warrants and represents that Employee has not filed any pending complaint,
charge, claim or grievance concerning Employee’s compensation, 

  
 3 

 
separation from employment or terms and conditions of employment against the Company with any local, state or federal agency, court or commission, and that if any agency, commission or court
assumes jurisdiction of any such complaint or charge on behalf of Employee, Employee will immediately request that agency, commission, or court to dismiss such proceeding. 

10.    Confidential Information. 

(a)    Definitions. For purposes of this Agreement, “Confidential Information” means information, to the
extent it is not a trade secret, that is possessed by or developed for Company and/or its related entities and that relates to the business or technology of Company and/or its related entities, including but not limited to compounds, formulations,
strategic plans, methods, products, procedures, processes, techniques, designs, job organization systems, business plans and strategies, existing or proposed bids, bidding strategies, technical developments, existing or proposed research projects,
financial or business projections, investments, marketing plans and strategies, pricing and cost information, negotiation strategies, sales strategies and plans, training information and materials, Company employee compensation and other Company
employee information, customer or potential customer lists, customer purchasing history, information generated for customer engagements, and other similar confidential and proprietary information. Confidential Information also includes information
received by Company from others which Company has an obligation to treat as confidential, including information obtained in connection with customer engagements. Confidential Information shall not include information that is or becomes available to
the public through no wrongful act or omission of Employee or any other person under a duty of confidentiality to Company. 

(b)    Nondisclosure. Employee agrees that for 24 months following the Separation Date, Employee will not, directly
or indirectly, in any capacity, use or disclose, or cause to be used or disclosed, in any geographic area in which or to any person or entity to which such use or disclosure could harm the business interests of Company, any Confidential Information.
This provision does not prohibit Employee’s use of general skills acquired prior to or during employment by Company, as long as such use does not involve the use or disclosure of Confidential Information or trade secrets of the Company or any
of its related entities. While complying with this Section 10(b) to the greatest extent possible, nothing herein prohibits Employee from reporting possible violations of federal law or regulation to any governmental agency or making other
disclosures under the whistleblower provisions of federal or state law or regulation. Employee is not required to notify the Company if Employee makes such reports or disclosures. 

11.    Trade Secrets. Notwithstanding the provisions of paragraph 10, the parties agree that nothing in this
Agreement shall be construed to limit or negate any statutory or common law of torts or trade secrets, where such law provides Company or any of its related entities with broader protection than that provided in this Agreement. Employee shall not
use or disclose the trade secrets of Company or any of its related entities as long as they remain trade secrets. 

12.    Specific Performance. Employee acknowledges and agrees that irreparable injury to Company may result in the
event that Employee breaches any covenant in this Agreement, and that the remedy at law for the breach of any such covenant will be inadequate. If Employee engages in any act in violation of any provision of paragraph 10 or 11, Employee agrees
that 

  
 4 

 
Company shall be entitled to seek, in addition to such other remedies and damages that may be available to it by law or under this Agreement, to injunctive relief to enforce such provisions
without the necessity of posting a bond and its costs, expenses and attorney fees incurred in enforcing such provisions. 

13.    Mutual Non-Disparagement. Employee agrees to maintain a positive and
constructive attitude and demeanor towards the Company, its directors, officers, shareholders, employees and agents, and agrees to refrain from making derogatory comments or statements of a negative nature about the Company, its directors, officers,
shareholders, employees and agents, to anyone, including, but not limited to, current and former Company customers, employees, suppliers, vendors, and referral sources. The Company agrees to cause its officers to maintain a positive and constructive
attitude and demeanor towards the Employee and to refrain from making derogatory comments or statements of a negative nature about the Employee. 
 This
paragraph does not in any way (a) restrict or impede Employee from exercising protected rights, including rights under the National Labor Relations Act (NLRA) or the federal securities laws, including the Dodd-Frank Act, to the extent that such
rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the
law, regulation, or order, or (b) restrict or impede the Company’s ability to provide truthful information about the reasons for Employee’s termination in any legal or administrative proceedings, in response to inquiries from any
state unemployment insurance agency or in any regulatory filings, including filings with the Securities and Exchange Commission. The Company may also provide the following information in response to any request for a reference from any future
potential employer of Employee: Employee’s name, position and dates of employment. 
 14.    Return of Company
Property. Upon Company’s request, Employee agrees that Employee will return any and all Company records, files, keys, keyless entry cards, documents, confidential or proprietary information, computer equipment, CDs, computer software
programs, vehicles, credit cards and any other property owned by or belonging to the Company or any of its related entities in Employee’s possession or under Employee’s control without any originals or copies being kept by Employee or
conveyed to any other person. 
 15.    No Representations as Employee. After the Separation Date, Employee
agrees that Employee will not represent herself as being a current employee, officer, attorney, agent or representative of Company for any purpose. 

16.    No Injuries. Employee acknowledges and agrees that Employee has reported to Company management any and all
workplace injuries (if any) sustained by Employee during Employee’s employment with the Company and that Employee is not aware of any facts that would give rise to a worker’s compensation claim that has not already been properly reported.

 17.    Binding Agreement. This Agreement shall be binding upon Employee and upon Employee’s heirs,
administrators, representatives, executors, successors and assigns and shall inure to the benefit of the Releases and to their heirs, administrators, representatives, executors, successors and assigns. This Agreement shall be binding upon the
Releases and their heirs, administrators, representatives, executors, successors and assigns and shall inure to the benefit of Employee and her heirs, administrators, representatives, executors, successors and assigns. 

  
 5 

 18.    Severability. It is understood and agreed that the provisions
of this Agreement shall be deemed severable, and the invalidity or unenforceability of any one or more of the provisions herein shall not affect the validity and enforceability of the other provisions herein. 

19.    Complete and Exclusive Agreement. The parties understand and agree that this Agreement is final and binding
and constitutes the complete and exclusive statement of the terms and conditions of settlement, that no representations or commitments were made by the parties to induce this Agreement other than as expressly set forth herein and that this Agreement
is fully understood by the parties. This Agreement may not be modified or supplemented except by a subsequent written agreement signed by the party against whom enforcement is sought. 

20.    Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered
one and the same agreement. Signatures to this Agreement transmitted by facsimile, by electronic mail in portable document format (.pdf) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a
document will have the same effect as physical delivery of the paper document bearing the original signature. 

21.    Jurisdiction and Venue. This Agreement shall be governed by and construed in accordance with the laws of the
State of Florida, without regard to principles of conflicts of law. Any controversy between Company and Employee arising under or relating to this Agreement shall be determined by a state or federal court located in Miami Dade County, Florida, and
the parties agree not to present any such controversy to any other court or forum. The parties expressly consent to the exclusive jurisdiction of a state or federal court located in Miami Dade County, Florida. 

22.    Consideration Period. Employee represents and agrees that Employee has had the opportunity and time to
consult with legal counsel concerning the provisions of this Agreement, if Employee so chooses and that Employee has been given an adequate amount of time to consider this Agreement. Employee acknowledges and agrees that in signing this Agreement,
Employee does not rely and has not relied upon any representation or statement by any of the Releases’ agents, employees, representatives, or attorneys with regard to the subject matter, basis, or effect of this Agreement. 

23.    Company Right to Revoke. The parties understand and agree that the Company has the right to revoke its offer
at any time prior to Employee’s signing of this Agreement and return of it to the Company, for any reason including, without limitation, Employee’s making of derogatory comments or statements of a negative nature about the Company, its
directors, officers, shareholders, employees and agents to anyone, including, but not limited to, current and former Company customers, employees, suppliers, vendors, and referral sources. 

24.    Code Section 409A. This Agreement is intended to satisfy the requirements for the
deferral of compensation under section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) or an exemption thereunder. All terms used in this Agreement shall be 

  
 6 

 
interpreted to the maximum extent possible to satisfy Code section 409A. Notwithstanding anything herein to the contrary, payments provided under this Agreement may be made upon a
permissible payment event in a manner that complies with Code section 409A or an applicable exemption. Any right to a series of installment payments pursuant to this Agreement is to be treated as a right to a series of separate payments. Any
separate payment or benefit under this Agreement or otherwise that may be excluded from Code section 409A as separation pay, a short-term deferral or any other applicable exemption or provision of Code section 409A shall be excluded from
Code section 409A to the maximum extent possible. Notwithstanding anything herein to the contrary, the Company may amend this Agreement, with the consent of Employee, to add, alter or remove any provision that the Company deems necessary,
appropriate or advisable to comply with Code section 409A. If there is more than one way to add, alter or remove a provision to comply with Code section 409A, the Company shall have the discretion to choose the alternative it believes to
be in the best interest of Employee and the Company. 
 25.    Acknowledgment. The undersigned parties
acknowledge and agree that they have carefully read the foregoing document, that a copy of the document was available to them prior to execution, that they understand its contents including its release of claims, that they have been given the
opportunity to ask any questions concerning the Agreement and its contents, and have signed this Agreement as their free and voluntary act. 

26.    Miscellaneous. 

(a)    All provisions in this Agreement, including subparagraphs, are severable, and the unenforceability of any provision
shall not affect the enforceability of any other provision. The parties agree that each covenant contained in paragraphs 10 and 11 hereof is separate and independent. If any provision of this Agreement is held to be unenforceable, then this
Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable provision, and the rest of the Agreement, valid and enforceable. If a court declines to amend this Agreement as provided herein, the invalidity or
unenforceability of any provision of this Agreement shall not affect the validity or enforceability of the remaining provisions, which shall be enforced as if the offending provision had not been included in this Agreement. 

(b)    Company may assign this Agreement to a successor entity without notification to, or the consent of, Employee. This
Agreement shall be binding upon Employee, and shall inure to the benefit of Company, its successors and assigns. 

(c)    The failure by Company to enforce any right or remedy available to it under this Agreement shall not be construed to
be a waiver of such right or remedy with respect to any other prior, concurrent or subsequent breach or failure. No waiver of rights under this Agreement shall be effective unless made in writing with specific reference to this Agreement. 

(d)    Only as to any portion(s) of any prior agreement(s) that concern(s) the specific subject matter contained in this
Agreement, this Agreement supersedes any prior agreement concerning similar subject matter dated prior to the date of this Agreement, and by execution of this Agreement, both parties agree that any such predecessor agreement shall be deemed null and
void. Unless contained herein, no representation, promise or agreement 

  
 7 

 
concerning the specific subject matter contained in this Agreement shall be binding on Company. This Agreement may not be modified orally or by conduct. Any modification of this Agreement must be
in a writing that refers to this Agreement and is signed by both parties. 
 IN WITNESS WHEREOF, the parties herein executed this
Separation Agreement and General Release as of the date appearing next to their signatures. 
  

							
		 		 	VERU INC.
				
	Date: January 9, 2018	 		 	By:	 	/s/ Mitchell Steiner
		 		 		 	Mitchell Steiner, MD, FACS
		 		 		 	Chief Executive Officer & President

 CAUTION: THIS IS A RELEASE. THE COMPANY HEREBY 

ADVISES EMPLOYEE TO CONSULT WITH AN ATTORNEY AND READ IT BEFORE 

SIGNING. 
  

							
				
	Date: January 8, 2018	 		 		 	/s/ Daniel Haines
		 		 		 	Daniel T. Haines

  
 8Exhibit 10.1

 

EXECUTION VERSION

 

CONSENT AND SIXTH AMENDMENT

TO

LOAN AND SECURITY AGREEMENT

 

This Consent and Sixth Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 9th day of January, 2018, by and between SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation with an office located at 780 Dedham Street, Suite 800, Canton, Massachusetts 02021 (“Borrower”).

 

RECITALS

 

A.                                    Bank and Borrower have entered into that certain Loan and Security Agreement dated as of August 28, 2012, as amended by that certain First Amendment to Loan and Security Agreement dated as of January 31, 2014, by and between Borrower and Bank, as amended by that certain Assumption and Second Amendment to Loan and Security Agreement (the “Second Amendment”) dated as of August 12, 2014, by and between Borrower and Bank, as amended by that certain Third Amendment to Loan and Security Agreement dated as of September 25, 2014, by and between Borrower and Bank, as further amended by that certain Fourth Amendment to Loan and Security Agreement dated as of October 31, 2014, by and between Borrower and Bank, and as further amended by that certain Consent and Fifth Amendment to Loan and Security Agreement dated as of December 31, 2015, by and between Borrower and Bank (as the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”).

 

B.                                    Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.

 

C.                                    Borrower has requested that Bank amend the Loan Agreement to (i) provide for a new term loan facility to Borrower, (ii) consent to the Subsidiary Formation (as defined herein) and (iii) make certain revisions to the Loan Agreement as more fully set forth herein.

 

D.                                    Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

 

1.                                      Definitions.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

 

2.                                      Amendments to Loan Agreement.

 

2.1                               Section 1 (Loans).  Section 1 of the Loan Agreement is amended by 

 

 

inserting the words “2017 Final Payment, 2017 Prepayment Fee, NewCo Reimbursement Obligations” immediately following the words “Final Payment,” appearing therein.

 

2.2                               Section 3.10 (Additional Agreements).  Section 3.10 of the Loan Agreement is amended by inserting the following sentence to appear at the end of Section 3.10 thereof:

 

“Notwithstanding the foregoing, Borrower and Bank hereby agree that the covenants set forth in this Section 3.10 do not apply to NewCo.”

 

2.3                               Section 4 (Term).  Section 4 of the Loan Agreement is amended by deleting the words “Growth Capital Maturity Date” appearing therein and inserting the words “2017 Term Loan Maturity Date” in lieu thereof.

 

2.4                               Section 5 (Events of Default).  Section 5 of the Loan Agreement is amended by (i) deleting the word “or” appearing before subsection (x), (ii) deleting the “.” appearing in the final sentence thereof, and (ii) inserting the following subsection (xi) appearing therein:

 

“                                          ; (xi) Borrower fails to deliver to Bank a duly executed Amended and Restated Loan and Security Agreement, in form and substance satisfactory to Bank, along with such documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate, on or prior to March 31, 2018; or (xii) Borrower fails to cause NewCo to transfer all balances in the Sales Account within one (1) Business Day after the Minimum Quarterly Payment for such calendar quarter has been satisfied (as provided in the Commercialization Agreement), to an account in the name of Borrower maintained with Bank.”

 

2.5                               Schedule A (Loan Terms).  Schedule A of the Loan Agreement is amended by inserting the following new section entitled “2017 Term Loan” to appear following the section entitled “Growth Capital Term Loan” therein:

 

2017 Term Loan

 

	
2017 Term Loan:
    	
 
    	
Subject to the terms and conditions of this   Agreement, and upon the delivery by Borrower to Bank of a completed and   executed irrevocable LOAN PAYMENT/ADVANCE REQUEST FORM (in a form   acceptable to Bank) on or about the Sixth Amendment Effective Date, Bank   shall make one (1) Loan to Borrower in an original principal amount of   Eleven Million Five Hundred Thousand Dollars ($11,500,000.00) (the “2017 Term Loan”); provided that, all or a portion of the   2017 Term Loan shall be used to repay in full Borrower’s outstanding   obligations and liabilities to Bank with respect to the Growth Capital Term A   Loan and the Growth Capital Term B Loans (including the Final Payment in an   amount of Twenty-One Thousand Five Hundred Sixteen
    

 

2

 

	
 
    	
 
    	
and 15/100 Dollars ($21,516.15)). Borrower hereby   authorizes Bank to apply such proceeds to the outstanding obligations under   the Growth Capital Term A Loan and Growth Capital Term B Loans as part of the   funding process without actually depositing such funds in an account of   Borrower. After repayment, the 2017 Term Loan (or any portion thereof) may   not be reborrowed.  

 

Bank will be obligated to make the 2017 Term Loan,   so long as (i) each of the representations and warranties in   Section 3 of the Agreement is materially true on the date the LOAN   PAYMENT/ADVANCE REQUEST FORM is submitted and on the Sixth Amendment   Effective Date (except to the extent they relate specifically to an earlier   date, in which case such representation and warranties shall continue to have   been true and accurate in all material respects as of such specified date),   and (ii) no Event of Default shall have occurred and be continuing or   result from the 2017 Term Loan.
    
	
 
    	
 
    	
 
    
	
2017 Term Loan Maturity Date:
    	
 
    	
December 1, 2022 (the “2017 Term   Loan Maturity Date”).
    
	
 
    	
 
    	
 
    
	
Repayment:
    	
 
    	
Commencing on the 2017 Term Loan Amortization Date   and continuing on each Payment Date thereafter, Borrower shall repay the 2017   Term Loan in (i) equal consecutive monthly installments of principal   based on the Repayment Schedule, plus (ii) monthly payments of accrued   interest at the rate set forth below. All outstanding principal and accrued   and unpaid interest under the 2017 Term Loan, and all other outstanding   Obligations with respect to the 2017 Term Loan, are due and payable in full   on the 2017 Term Loan Maturity Date.
    
	
 
    	
 
    	
 
    
	
Interest Rate:
    	
 
    	
The 2017 Term Loan shall accrue interest on the   outstanding principal balance at a floating per annum rate of three-quarters   of one percent (0.75%) above the Prime Rate. The interest rate increases or   decreases when the Prime Rate changes. Interest is computed on a 360 day year   for the actual number of days elapsed.
    
	
 
    	
 
    	
 
    
	
Default Rate:
    	
 
    	
Any amounts outstanding during the continuance of an   Event of Default shall bear additional interest at the rate of five percent   (5.0%) per annum.
    
	
 
    	
 
    	
 
    
	
Permitted Prepayment:
    	
 
    	
Borrower shall have the option to prepay all (but   not less than all) of the 2017 Term Loan provided Borrower (i) provides
    

 

3

 

	
 
    	
 
    	
written notice to Bank of its election to prepay the   2017 Term Loan at least five (5) days prior to such prepayment, and   (ii) pays, on the date of such prepayment (A) all outstanding   principal and accrued interest under the 2017 Term Loan, (B) the 2017   Prepayment Fee, (C) the 2017 Final Payment, and (D) all other sums,   if any, that shall have become due and payable, including interest at the   Default Rate with respect to any past due amounts.
    
	
 
    	
 
    	
 
    
	
Mandatory Prepayment:
    	
 
    	
If the 2017 Term Loan is accelerated following the   occurrence of an Event of Default or otherwise, Borrower shall immediately   pay to Bank an amount equal to the sum of: (i) all outstanding principal   and accrued interest under the 2017 Term Loan, (ii) the 2017 Prepayment   Fee, (iii) the 2017 Final Payment, and (iii) all other sums, if   any, that shall have become due and payable, including interest at the   Default Rate with respect to any past due amounts.
    
	
 
    	
 
    	
 
    
	
Request to Debit Accounts:
    	
 
    	
Bank may debit any of Borrower’s deposit accounts   (including account number(s): xxxxxxx928) at Bank for principal and interest   payments or any amounts Borrower owes Bank when due. Bank will notify   Borrower when it debits Borrower’s accounts. Such debits are not a set-off.   Payments received after 12:00 noon Eastern time are considered received at   the opening of business on the next Business Day. When a payment is due on a   day that is not a Business Day, the payment is due the next Business Day and   additional interest shall accrue.
    

 

2.6                               Schedule A (Loan Terms).  Schedule A of the Loan Agreement is amended by deleting the following section entitled “Fees” and inserting in lieu thereof the following:

 

FEES

 

	
Final Payment:    
    	
Borrower will pay the Final Payment, when due   hereunder.
    
	
 
    	
 
    
	
Commitment Fee: 
    	
Borrower will pay on the Effective Date a fully   earned, non-refundable commitment fee of Five Thousand Dollars ($5,000.00).
    
	
 
    	
 
    
	
2017 Final Payment:  
    	
Borrower will pay the 2017 Final Payment, when due   hereunder.
    
	
 
    	
 
    
	
2017 Prepayment Fee: 
    	
Borrower will pay the 2017 Prepayment Fee, when due   hereunder.
    

 

4

 

2.7                               Schedule A (Loan Terms).  Schedule A of the Loan Agreement is amended by deleting the provision entitled “Banking Matters” in its entirety and inserting in lieu thereof the following:

 

BANKING MATTERS

 

	
Banking   Matters:
    	
Borrower shall maintain all of its and all of its Subsidiaries’   (excluding NewCo and Securities Corp.) operating, depository and securities   accounts with Bank and Bank’s Affiliates, provided, further, Borrower   (individually and not on a consolidated basis) shall at all times have on   deposit in operating, depository and securities accounts maintained with Bank   or Bank’s Affiliates, cash in an amount equal to or greater than one hundred   five percent (105.0%) of the then-outstanding Obligations of Borrower to   Bank. Bank may restrict withdrawals or transfers by or on behalf of Borrower   that would violate this provision, regardless of whether an Event of Default   exists at such time. In addition to the foregoing, Borrower shall conduct all   of its cash management, Letters of Credit, and foreign exchange banking with   Bank and Bank’s Affiliates.”
    

 

2.8                               Schedule A (Loan Terms).  Schedule A of the Loan Agreement is amended by deleting the section entitled “Financial Covenant” in its entirety and inserting in lieu thereof the following:

 

FINANCIAL COVENANT

 

	
Liquidity   Ratio:
    	
Borrower shall maintain   at all times, to be tested as of the last day of each month, a Liquidity   Ratio of at least 2.0 to 1.0.
    

 

5

 

2.9          Schedule A (Loan Terms).  Schedule A of the Loan Agreement is amended by inserting the following new section entitled “Post-Closing Conditions” to appear immediately following the section entitled “Financial Covenant”:

 

	
 
    	
POST-CLOSING CONDITIONS
    

 

	
Post-Closing Conditions: 
    	
Within thirty (30) days after the Sixth Amendment   Effective Date, Bank shall have received (i) updated evidence   satisfactory to Bank that the insurance certificates and policies required by   Section 3.5 hereof are in full force and effect and (ii) evidence   showing lender’s loss payable and/or additional insured clauses and   cancellation notice (or endorsements reflecting same) in favor of Bank   (collectively, the “Post-Closing   Deliverables”). Borrower’s failure to provide the Post-Closing   Deliverables within thirty (30) days after the Sixth Amendment Effective Date   shall result in an immediate Event of Default for which there shall be no   grace or cure period.
    

 

2.1                               Schedule B (Collateral).  Schedule B of the Loan Agreement is amended in its entirety and replaced with the Schedule B attached as Exhibit 1 hereto.

 

2.2          Schedule C (Definitions).  The following new terms and their respective definitions are inserted to appear alphabetically on Schedule C of the Loan Agreement:

 

“              “2017 Final Payment” is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of (a) the 2017 Term Loan Maturity Date, (b) the repayment of the 2017 Term Loan in full, (c) as required pursuant to Schedule A, or (d) the termination of this Agreement, equal to Seven Hundred Eighteen Thousand Seven Hundred Fifty Dollars ($718,750.00).”

 

“              “2017 Prepayment Fee” shall be an additional fee payable to Bank, with respect to the 2017 Term Loan, in an amount equal to:

 

(a)           for a prepayment of the 2017 Term Loan made on or prior to the first (1st) anniversary of the Sixth Amendment Effective Date, three percent  (3.0%) of the then outstanding principal amount of the 2017 Term Loan immediately prior to such prepayment;

 

(b)           for a prepayment of the 2017 Term Loan made after the first (1st) anniversary of the Sixth Amendment Effective Date, but on or prior to the second (2nd) anniversary of the Sixth Amendment Effective Date, two percent (2.0%) of the then outstanding principal amount of the 2017 Term Loan immediately prior to such prepayment; and

 

6

 

(c)           for a prepayment made after the second (2nd) anniversary of the 2017 Term Loan, but prior to the 2017 Term Loan  Maturity Date, one percent (1.0%) of the then outstanding principal amount of the 2017 Term Loan immediately prior to such prepayment.

 

Notwithstanding the foregoing, Bank agrees to waive the 2017 Prepayment Fee if Bank closes on the refinance and re-documentation of the 2017 Term Loan (in its sole and absolute discretion) on or prior to the 2017 Term Loan Maturity Date.”

 

“              “2017 Term Loan” is defined in Schedule A.”

 

“              “2017 Term Loan Amortization Date” is July 1, 2019; provided that, upon the occurrence of the Interest Only Extension Event, the 2017 Term Loan Amortization Date is January 1, 2020.”

 

“              “2017 Term Loan Maturity Date” is defined in Schedule A.”

 

“              “Application” means that certain Application and Letter of Credit dated as of even date hereof.”

 

“              “Cash Equivalents” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc.; (c) Bank’s certificates of deposit issued maturing no more than one (1) year after issue; and (d) money market funds at least ninety-five percent (95.0%) of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition.”

 

“              “Commercialization Agreement” means that certain Commercialization Agreement by and among Depomed, Inc., NewCo, and Borrower, dated as of December 4, 2017, as amended by that certain Amendment No. 1, dated as of January 9, 2018, as in effect on the Sixth Amendment Effective Date.”

 

“              “EBITDA” means, as calculated on a consolidated basis with respect to Borrower and its Subsidiaries, (a) Net Income, plus (b) Interest Expense, plus (c) to the extent deducted in the calculation of Net Income, depreciation expense and amortization expense, plus (d) income tax expense.”

 

“              “Excluded Sublicenses” are sublicenses granted by NewCo to Borrower pursuant to the Commercialization Agreement.”

 

7

 

“              “Interest Expense” means for any fiscal period, interest expense (whether cash or non-cash) determined in accordance with GAAP for the relevant period ending on such date, including, in any event, interest expense with respect to any Loan and other Indebtedness of Borrower and its Subsidiaries, including, without limitation or duplication, all commissions, discounts, or related amortization and other fees and charges with respect to letters of credit and bankers’ acceptance financing and the net costs associated with interest rate swap, cap, and similar arrangements, and the interest portion of any deferred payment obligation (including leases of all types).”

 

“              “Interest Only Extension Event” means confirmation by Bank in writing that Borrower has achieved (calculated on a consolidated basis with respect to Borrower and its Subsidiaries) EBITDA in excess of Two Million Five Hundred Thousand Dollars ($2,500,000.00) for two (2) consecutive calendar quarters for the period commencing as of the Sixth Amendment Effective Date and ending on June 30, 2019.”

 

“              “Liquidity Ratio” means, as of any date of determination, a ratio of (a) the aggregate amount of unrestricted and unencumbered cash and Cash Equivalents of Borrower maintained at Bank or Bank’s Affiliates, to (b) the aggregate amount of outstanding obligations and liabilities with respect to (i) the NewCo Reimbursement Obligations plus (ii) Bank Services.”

 

“              “Minimum Quarterly Payment” has the meaning as defined in the Commercialization Agreement.”

 

“              “Net Income” means, as calculated on a consolidated basis for Borrower and its Subsidiaries for any period as at any date of determination, the net profit (or loss), after provision for taxes, of Borrower and its Subsidiaries for such period taken as a single accounting period.”

 

“              “NewCo” means Collegium NF, LLC, a Delaware limited liability company and a wholly-owned Subsidiary of Borrower.”

 

“              “NewCo Letter of Credit” means a certain letter of credit issued by Bank on behalf of NewCo in favor of Depomed, Inc., in the face amount of Thirty-Three Million Seven Hundred Fifty Thousand Dollars ($33,750,000.00), pursuant to the terms of the Application, which by its terms expires on the one (1) year  anniversary thereof (as automatically extended in accordance with its terms), subject to extension pursuant to the terms thereof, as may be amended, modified, supplemented and/or restated from time to time.”

 

“              “NewCo Reimbursement Obligations” means all of NewCo’s obligations and liabilities under the NewCo Letter of Credit (including reimbursement obligations as provided under the Application).”

 

8

 

“              “Payment-Bearing Products” has the meaning as defined in the Commercialization Agreement.”

 

“              “Post-Closing Deliverables” is defined in Schedule A.

 

“              “Repayment Schedule” means, forty-two (42) monthly payments of principal; provided that, upon the occurrence of the Interest Only Extension Event, the Repayment Schedule shall be thirty-six (36) monthly payments of principal.”

 

“              “Sales Account” means account number XXXXXXXX928 in the name of NewCo and maintained with Bank.”

 

“              “Sixth Amendment Effective Date” is January 9, 2018.

 

2.3          Schedule C (Definitions).  The following term and its respective definition appearing in Schedule C of the Loan Agreement is amended in its entirety and replaced with the following:

 

“              “Prime Rate” is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the “prime rate” then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement; and provided further that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Bank, the “Prime Rate” shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement.”

 

2.4          Schedule E (Compliance Certificate).   Schedule E of the Loan Agreement is amended in its entirety and replaced with the Schedule E attached as Exhibit 2 hereto.

 

2.5          Guaranty.  Borrower irrevocably, absolutely, and unconditionally guarantees to Bank the prompt and complete payment and performance when due (whether at stated maturity by acceleration or otherwise) of all of the obligations in connection with any sum, now or hereafter due relating to the NewCo Letter of Credit (including the NewCo Reimbursement Obligations).

 

3.             Limitation of Amendments.

 

3.1          The amendments set forth in Section 2, above, are effective for the 

 

9

 

purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.

 

3.2          This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

 

4.             Consent.  Borrower has notified Bank that Borrower intends to create NewCo (the “Subsidiary Formation”).  Borrower has requested that Bank consent to the Subsidiary Formation.  In addition, Borrower has notified Bank that Borrower has entered or will enter into certain transactions with NewCo and Depomed, Inc. pursuant to the Commercialization Agreement (the “Commercialization Agreement Transactions”). Bank hereby consents to the Subsidiary Formation and the Commercialization Agreement Transactions and agrees that neither the Subsidiary Formation nor the Commercialization Agreement Transactions shall, in and of themselves, constitute an “Event of Default” under the Loan Agreement, including Section 3.10(i) (relative to Borrower’s funds from gross sales of the Payment-Bearing Products being transferred to NewCo pursuant to the terms of the Commercialization Agreement), Section 3.10(iv) (relative to mergers or acquisitions), Section 3.10(vii) (relative to Permitted Investments), or Section 3.10(x) (relative to transactions with affiliates) thereof.  Borrower hereby acknowledges and agrees that nothing in this Section 4 or anywhere in this Amendment shall be deemed or otherwise construed as a waiver by Bank of any of its rights and remedies pursuant to the Loan Documents, applicable law or otherwise.

 

5.             Representations and Warranties.  To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:

 

5.1          Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

 

5.2          Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

 

5.3          The organizational documents of Borrower delivered to Bank on the Second Amendment Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect, except as set forth on Exhibit 2 annexed to the Second Amendment;

 

5.4          The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;

 

10

 

5.5                               The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

 

5.6                               The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and

 

5.7                               This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

 

6.                                      Updated Schedule D.   Borrower has delivered an updated Schedule D (Statement of Borrower’s Information) to the Loan Agreement in connection with this Amendment attached hereto as Exhibit 3 (the “Updated Schedule D”), which Updated Schedule D shall supersede in all respects that certain Schedule D (Statement of Borrower’s Information) to the Loan Agreement previously delivered by Borrower to Bank in connection with the Second Amendment.  Borrower agrees that all references in the Loan Agreement to “Schedule D” shall hereinafter be deemed to be a reference to the Updated Schedule D.

 

7.                                      Integration.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

 

8.                                      Counterparts.  This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

 

9.                                      Effectiveness.  This Amendment shall be deemed effective upon (a) the due execution and delivery to Bank of this Amendment by each party hereto and (b) Borrower’s payment of Bank’s legal fees and expenses incurred in connection with this Amendment.

 

[Signature page follows.]

 

11

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as a sealed instrument under the laws of the Commonwealth of Massachusetts as of the date first written above.

 

	
BANK
    
	
 
    
	
SILICON   VALLEY BANK
    
	
 
    
	
By:
    	
/s/   Ryan Roller
    	
 
    
	
Name:
    	
Ryan   Roller
    	
 
    
	
Title:
    	
Vice   President
    	
 
    

 

 

	
 BORROWER
    
	
 
    
	
COLLEGIUM   PHARMACEUTICAL, INC.
    
	
 
    
	
By:
    	
/s/   Paul Brannelly
    	
 
    
	
Name:
    	
Paul   Brannelly
    	
 
    
	
Title:
    	
Chief   Financial Officer
    	
 
    

 

 

SCHEDULE B

COLLATERAL

 

The Collateral consists of all of Borrower’s right, title and interest in and to the following personal property as such terms are defined under the Massachusetts Uniform Commercial Code:

 

All goods, equipment, inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, general intangibles (including payment intangibles), accounts (including health-care receivables), documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, certificates of deposit, deposit accounts, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and

 

all Borrower’s Books relating to the foregoing and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

 

Notwithstanding the foregoing, the Collateral does not include (a) any equity interests of Borrower in NewCo, (b) the Excluded Sublicenses, (c) any Intellectual Property of Borrower; provided, however, the Collateral shall include all accounts, license and royalty fees and other revenues, proceeds, or income arising out of or relating to any of the foregoing Intellectual Property of Borrower, or (d) any accounts directly resulting from the sale of the Payment-Bearing Products and any cash, royalty fees, revenues, proceeds or income directly resulting from any of the foregoing Payment-Bearing Products; provided, however, the Collateral shall include all cash deposited in accounts in Borrower’s bank or securities accounts in Borrower’s name, including transfers by NewCo to Borrower pursuant to Section 7.7(b)(ii) of the Commercialization Agreement.

 

For purposes hereof, the following terms have the following meanings:

 

“Borrower’s Books” means all Borrower’s books and records including ledgers, records regarding Borrower’s assets or liabilities, the Collateral, business operations or financial condition and all computer programs or discs or any equipment containing the information.

 

“Excluded Sublicenses” are sublicenses granted by NewCo to Borrower pursuant to that certain Commercialization Agreement by and among Depomed, Inc., NewCo, and Borrower, dated as of December 4, 2017.”

 

“Intellectual Property” means any copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, service marks and applications therefor, whether registered or not, and the goodwill of the business of Borrower connected with and symbolized thereby, know-how, operating manuals, trade secret rights, rights to unpatented inventions, domain names, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

 

“NewCo” means Collegium NF, LLC, a Delaware limited liability company and a wholly-owned Subsidiary of Borrower.

 

Pursuant to the terms of a certain negative pledge arrangement with Bank, Borrower has agreed not to encumber any of its copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, and the goodwill of the business of Borrower connected with and symbolized thereby, know-how, operating manuals, trade secret rights, rights to unpatented inventions, domain names, and any claims for damage by way of any past, present, or future infringement of any of the foregoing, without Bank’s prior written consent.

 

 

Exhibit 2

 

SCHEDULE E

 

COMPLIANCE CERTIFICATE

 

TO:                           SILICON VALLEY BANK

 

FROM: COLLEGIUM PHARMACEUTICAL, INC.

 

The undersigned authorized officer of COLLEGIUM PHARMACEUTICAL, INC., a Delaware corporation (“Borrower”) certifies that under the terms and conditions of the Loan and Security Agreement between Borrower and Bank dated August 28, 2012 (as has been and may be amended, restated or modified from time to time, the “Agreement”), (i) Borrower is in complete compliance for the period ending                 with all required covenants except as noted below and (ii) all representations and warranties in the Agreement are true and correct in all material respects on this date (except to the extent they relate specifically to an earlier date, in which case such representations and warranties shall continue to have been true and correct as of such specified date).  In addition, the undersigned authorized officer of Borrower certifies that Borrower and each Subsidiary has timely filed all required tax returns and paid, or made adequate provision to pay, all material taxes, except those being contested in good faith with adequate reserves under GAAP.  Attached are the required documents supporting the certification.  The Officer certifies that these are prepared in accordance with Generally Accepted Accounting Principles (GAAP) consistently applied from one period to the next except as explained in an accompanying letter or footnotes.  The Officer acknowledges that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered.

 

Please indicate compliance status by circling Yes/No under “Complies” column.

 

	
Reporting Covenant
    	
 
    	
Required
    	
 
    	
Complies
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Monthly financial statements + CC
    	
 
    	
Monthly within 30 days
    	
 
    	
Yes
    	
 
    	
No
    
	
Annual (Audited) financial statements
    	
 
    	
FYE within 180 days
    	
 
    	
Yes
    	
 
    	
No
    
	
Board-approved projections
    	
 
    	
FYE within 60 days
    	
 
    	
Yes
    	
 
    	
No
    

 

Borrower only has deposit accounts located at the following institutions:                    .

 

	
Financial Covenant
    	
 
    	
Required
    	
 
    	
Actual
    	
 
    	
Complies
    
	
Liquidity Ratio
    	
 
    	
2.0:1.0
    	
 
    	
   :1.0
    	
 
    	
Yes
    	
 
    	
No
    

 

The following financial covenant analysis and information set forth in Schedule 1 attached hereto are true and accurate as of the date of this Certificate.

 

 

 

	
Comments Regarding Exceptions:   See Attached.
    	
 
    	
BANK   USE ONLY
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Received by:
    	
 
    
	
Sincerely,
    	
 
    	
AUTHORIZED SIGNER
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Date:
    	
 
    
	
COLLEGIUM   PHARMACEUTICAL, INC.
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Verified:
    	
 
    
	
SIGNATURE
    	
 
    	
AUTHORIZED SIGNER
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Date:
    	
 
    
	
TITLE
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Compliance   Status:
    	
Yes
    	
No
    
	
DATE
    	
 
    	
 
    
							

 

 

Schedule 1 to Compliance Certificate

 

Financial Covenants of Borrower

 

In the event of a conflict between this Schedule and the Loan Agreement, the terms of the Loan Agreement shall govern.

 

	
Dated:
    	
 
    	
 
    

 

I.                                        Liquidity Ratio (Schedule A)

 

Required:                                           Borrower shall maintain at all times, to be tested as of the last day of each month, a ratio of (a) the aggregate amount of unrestricted and unencumbered cash and Cash Equivalents of Borrower maintained at Bank or Bank’s Affiliates, to (b) the aggregate amount of outstanding obligations and liabilities with respect to (i) the NewCo Reimbursement Obligations and (ii) Bank Services of at least 2.0 to 1.0.

 

Actual:            :1.0

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]